帮助 关于我们

返回检索结果

Short-term Rosuvastatin Treatment for the Prevention of Contrast-induced Acute Kidney Injury in Patients Receiving Moderate or High Volumes of Contrast Media: A Sub-analysis of the TRACK-D Study

查看参考文献21篇

文摘 Background: Current randomized trials have demonstrated the effects of short-term rosuvastatin therapy in preventing contrast-induced acute kidney injury (CIAKI). However, the consistency of these effects on patients administered different volumes of contrast media is unknown. Methods: In the TRACK-D trial, 2998 patients with type 2 diabetes and concomitant chronic kidney disease (CKD) who underwent coronary/peripheral arterial angiography with or without percutaneous intervention were randomized to short-term (2 days before and 3 days after procedure) rosuvastatin therapy or standard-of-care. This prespecified analysis compared the effects of rosuvastatin versus standard therapy in patients exposed to (moderate contrast volume [MCV], 200-300 ml, n = 712) or (high contrast volume [HCV], ≥300 ml, n = 220). The primary outcome was the incidence of CIAKI. The secondary outcome was a composite of death, dialysis/hemofiltration or worsened heart failure at 30 days. Results: Rosuvastatin treatment was associated with a significant reduction in CIAKI compared with the controls (2.1% vs. 4.4%, P= 0.050) in the overall cohort and in patients with MCV (1.7% vs. 4.5%, P= 0.029), whereas no benefit was observed in patients with HCV (3.4% vs. 3.9%, P = 0.834). The incidence of secondary outcomes was significantly lower in the rosuvastatin group compared with control group (2.7% vs. 5.3%, P = 0.049) in the overall cohort, but it was similar between the patients with MCV (2.0% vs. 4.2%, P = 0.081) or HCV (5.1 % vs. 8.8%, P = 0.273). Conclusions: Periprocedural short-term rosuvastatin treatment is effective in reducing CIAKI and adverse clinical events for patients with diabetes and CKD after their exposure to a moderate volume of contrast medium.
来源 Chinese Medical Journal ,2015,128(6):784-789 【核心库】
DOI 10.4103/0366-6999.152620
关键词 Chronic Kidney Disease ; Contrast-induced Acute Kidney Injury ; Rosuvastatin
地址

1. Department of Cardiology, General Hospital of Shenyang Military Region, Liaoning, Shenyang, 110840  

2. Department of Cardiology, First Hospital of Liaoning Medical College, Liaoning, Jinzhou, 110840  

3. Department of Cardiology, General Hospital of People's Liberation Army, Beijing, 100853  

4. Department of Cardiology, The Second Artillery General Hospital of People's Liberation Army, Beijing, 100088  

5. Department of Cardiology, No. 252 Hospital of People's Liberation Army, Hebei, Baoding, 071000

语种 英文
文献类型 研究性论文
ISSN 0366-6999
学科 临床医学
基金 Key Project of National 12~(th) Five-Year Research Program of China ;  supported by grants from the Key Technologies R and D Project of Liaoning Province
文献收藏号 CSCD:5363389

参考文献 共 21 共2页

1.  Solomon R. Contrast-induced acute kidney injury. Circulation,2010,122:2451-2455 CSCD被引 17 次    
2.  Gruberg L. Acute renal failure requiring dialysis after percutaneous coronary interventions. Catheter Cardiovasc Interv,2001,52:409-416 CSCD被引 8 次    
3.  McCullough P A. Acute renal failure after coronary intervention: Incidence, risk factors, and relationship to mortality. Am J Med,1997,103:368-375 CSCD被引 37 次    
4.  Tepel M. Contrast-induced nephropathy: A clinical and evidence-based approach. Circulation,2006,113:1799-1806 CSCD被引 27 次    
5.  Han Y. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. J Am Coll Cardiol,2014,63:62-70 CSCD被引 26 次    
6.  Leoncini M. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: Results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome). J Am Coll Cardiol,2014,63:71-79 CSCD被引 11 次    
7.  Patti G. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty-Contrast-induced nephropathy] trial. Am J Cardiol,2011,108:1-7 CSCD被引 13 次    
8.  Ozhan H. Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography. Angiology,2010,61:711-714 CSCD被引 6 次    
9.  Jo S H. Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial-A randomized controlled study. Am Heart J,2008,155:499.e1-499.e8 CSCD被引 9 次    
10.  Mehran R. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: Development and initial validation. J Am Coll Cardiol,2004,44:1393-1399 CSCD被引 105 次    
11.  Nash K. Hospital-acquired renal insufficiency. Am J Kidney Dis,2002,39:930-936 CSCD被引 112 次    
12.  Munoz M A. Pravastatin versus simvastatin for prevention of contrast-induced nephropathy. J Cardiovasc Pharmacol Ther,2011,16:376-379 CSCD被引 1 次    
13.  Attallah N. The potential role of statins in contrast nephropathy. Clin Nephrol,2004,62:273-278 CSCD被引 16 次    
14.  Khanal S. Statin therapy reduces contrast-induced nephropathy: An analysis of contemporary percutaneous interventions. Am J Med,2005,118:843-849 CSCD被引 21 次    
15.  Windecker S. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J,2014,35:2541-2619 CSCD被引 154 次    
16.  Ridker P M. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med,2008,359:2195-2207 CSCD被引 172 次    
17.  Deo S H. Statin therapy lowers muscle sympathetic nerve activity and oxidative stress in patients with heart failure. Am J Physiol Heart Circ Physiol,2012,303:H377-H385 CSCD被引 6 次    
18.  Ichiki T. Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol,2001,21:1896-1901 CSCD被引 20 次    
19.  Hernandez-Perera O. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest,1998,101:2711-2719 CSCD被引 30 次    
20.  Bonetti P O. Statin effects beyond lipid lowering-Are they clinically relevant?. Eur Heart J,2003,24:225-248 CSCD被引 39 次    
引证文献 1 篇

1 刘同强 对比剂对维持性血液透析患者氧化应激状态的影响 南京医科大学学报. 自然科学版,2015,35(9):1252-1255
CSCD被引 0 次

显示所有1篇文献

论文科学数据集
PlumX Metrics
相关文献

 作者相关
 关键词相关
 参考文献相关

版权所有 ©2008 中国科学院文献情报中心 制作维护：中国科学院文献情报中心
地址：北京中关村北四环西路33号 邮政编码：100190 联系电话：(010)82627496 E-mail:cscd@mail.las.ac.cn 京ICP备05002861号-4 | 京公网安备11010802043238号